Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • xyzzy123
    Member
    • Dec 2011
    • 15

    #16
    I had guessed that January's drop was connected to Illumina's announcement in the same month, so was surprised that it reversed in April.

    Comment

    • AllSeq
      Registered Vendor
      • Oct 2013
      • 138

      #17
      Originally posted by xyzzy123 View Post
      I had guessed that January's drop was connected to Illumina's announcement in the same month, so was surprised that it reversed in April.
      My guess (and it's really just a guess) is that they are ignoring the X Ten in figuring the prices. Illumina has been raising prices on their sequencing kits every April 1st, so that little bump makes sense. However, I'm not sure that they're taking into account the release of the v4 chemistry for the HiSeq 2500. That reduced the list price for 1Gb of sequence from $43 down to $29. (For comparison, it's just $7/Gb for the HiSeq X.)
      AllSeq - The Sequencing Marketplace
      [email protected]
      www.AllSeq.com

      Comment

      • xyzzy123
        Member
        • Dec 2011
        • 15

        #18
        https://www.genome.gov/sequencingcosts/ is no longer being updated. It looks like they hit the end of the graph and don't want to extend it. In any case, since the price is now dropping much more _slowly_ than Moore's Law, in another 10 years or so at this rate Moore's Law will catch up and the graph would look kind of silly.

        Comment

        • xyzzy123
          Member
          • Dec 2011
          • 15

          #19
          NOW there's finally a sizable drop.

          Estimated cost of sequencing the human genome over time since the Human Genome Project.


          The last two entries in the .xlsx file show a cost per genome of $4,211 on Apr. 15 and $1,363 on Jul. 15. I guess they decided to take the X Ten into account.

          Comment

          • Brian Bushnell
            Super Moderator
            • Jan 2014
            • 2709

            #20
            Due to all the artificial limitations on the X10, I don't consider it an accurate reflection of real sequencing costs.

            Comment

            • westerman
              Rick Westerman
              • Jun 2008
              • 1104

              #21
              Originally posted by Brian Bushnell View Post
              Due to all the artificial limitations on the X10, I don't consider it an accurate reflection of real sequencing costs.
              Indeed. Those costs are misleading. There should be all sorts of asterisks detailing the assumptions. Might as well throw in the higher per-base cost of using PacBio to complete a genome.

              I've always hated that graph because of the misapplication of "Moore's Law". Stupid. But I have seen it in so many presentations that I just grit my teeth.

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
                by SEQadmin2



                CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

                Despite this, “CRISPR helped turn genome editing from a specialized technique into
                ...
                Today, 11:01 AM
              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                07-20-2026, 11:48 AM
              • SEQadmin2
                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by SEQadmin2



                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                ...
                07-09-2026, 11:10 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, Today, 02:55 AM
              0 responses
              7 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-24-2026, 12:17 PM
              0 responses
              12 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-23-2026, 11:41 AM
              0 responses
              12 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-20-2026, 11:10 AM
              0 responses
              24 views
              0 reactions
              Last Post SEQadmin2  
              Working...